R Clinical implications of slow acetylation: Increased risk of isoniazid-induced hepatotoxicity and peripheral neuropathy (tuberculosis treatment) R Increased risk of sulfonamide hypersensitivity reactions R Increased risk of aromatic amine-related bladder cancer in occupational exposure settings (dye workers, rubber industry) R Drug-induced lupus from hydralazine and procainamide occurs almost exclusively in slow acetylators R Altered caffeine metabolism (slow acetylators clear caffeine more slowly via the NAT2 pathway) R NAT1 polymorphisms are less well characterized but the slow allele NAT1*14 has been associated with increased risk of cancers from dietary aromatic amines
Lorestani, S., Bahari, A., Asadi, M., & Zahedi Avval, F
IV delivery bypasses your digestive system and puts glutathione directly into your bloodstream
NAT1 and NAT2 Slow Acetylators NAT2 has over 100 identified alleles, broadly classified as rapid , intermediate , and slow acetylator phenotypes
Abstract Glutathione S-transferase (GST) from Schistosoma japonicum has been widely used as a tag for affinity purification and pulldown of fusion proteins to detect proteinprotein interactions
When delivered intravenously, glutathione enters the bloodstream directly, offering faster and more effective absorption compared to oral supplements
